We report a nonadentate bispidine (3,7-diazabicyclo[3.3.1]nonane)
that unveils the potential to bind theranostically relevant radionuclides,
including indium-111, lutetium-177, and actinium-225 under mild labeling
conditions. This radiopharmaceutical candidate allows the simultaneous
application of imaging and treatment (radionuclide theranostics) without
changing the type of the bioconjugate; that is, it allows the strong
binding to an imaging and a therapeutic radionuclide by the same chelator.
Since sophisticated coordination chemistry is required to achieve
high thermodynamic and kinetic stability (inertness), it is not surprising
that only a few chelators have been reported that are able to strongly
bind several radionuclides to a satisfactory extent. Bispidine-derived
ligands have proven to be ideal for di- and trivalent metal ions with
generally fast complexation kinetics and high in vitro and in vivo stabilities. The presented (radio)complexes
are formed under mild conditions (pH 6, <40 °C) and exhibit
thermodynamic stability and inertness in human serum comparable to
the corresponding DOTA complexes. The bispidine-based complexing agent
was conjugated to a peptide, targeting somatostatin type 2 receptors
(SSTR2), overexpressed on neuroendocrine tumors. The 177Lu- and 225Ac-labeled conjugates were investigated, considering
their binding to two different SSTR2-positive cell lines, including
the human pancreatic carcinoid tumor (BON-SSTR2+) and the murine pheochromocytoma
cell line (MPC). The biodistribution and accumulation pattern in MPC
tumor-bearing mice was also evaluated. The LuIII and AcIII complexes studied show how ligand structures can be optimized
in general by extending the denticity and varying the donor set in
order to allow for fast complex formation and medically relevant inertness.